Seb Denby joins the team to support increased demand for Creative Places expertise across the UK
Friday 13th May 2022
Creative Places is delighted to welcome Seb Denby as Associate. An experienced Chartered Commercial Surveyor, Seb has over seven years’ experience of the agency, investment, acquisition and development markets both in Cambridge and across the UK.
Seb’s specific experience within the life science and R&D real estate sector…
Cambridge, UK 09 May 2022– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted a European patent covering its unique Binary Assembly method for gene synthesis. The patent (EP 3688189 B1) further strengthens Evonetix’s IP portfolio and is a key milestone in the Company’s strategy to simplify gene synthesis for users and enable a new generation of in-lab DNA synthesis platforms.Evonetix’s novel semiconductor-based synthesis chip uses precise temperature control to manage the DNA synthesis cycle at…
A new partnership between PrecisionLife and Sano Genetics will help advance researchers’ understanding of the drivers of long COVID, identifying at-risk patients and potential drug targets.
PRESS RELEASE
OXFORD, UK May 11, 2022
PrecisionLife Limited, a global techbio company using its deep insights into disease biology and patient stratification to drive precision medicine in chronic diseases, is pleased to announce a partnership with Sano Genetics, a genetic research platform enabling patients to participate in ethical research projects, to advance understanding of the long-term effects of…
Cambridge, England, May 4th, 2022 – Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, today announced a strategic collaboration with Merck Healthcare, a division of Merck. Under the terms of the agreement, Merck and Amphista will work collaboratively to discover and develop small molecule protein degraders for an initial three targets in oncology and immunology indications. Amphista will receive an upfront payment, R&D funding and success-based milestone payments of up to €893.5 million ($1.0 billion…
AMSBIO announce the launch of its StemFit Purotein® range of high purity, high activity recombinant proteins for cell therapy applications.
Continued expansion of cell therapy applications across healthcare and the life sciences is driving a rapidly increasing need for clinically applicable ancillary materials. A key requirement is for recombinant proteins, such as growth factors and cytokines. This demand for clinically applicable recombinant proteins places stringent requirements on product quality, lot-to-lot consistency, and compliance with all relevant laws and regulations.
All StemFit…
03 May 2022, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies targeting RNA epigenetic mechanisms, today announces that it has been awarded a Biomedical Catalyst grant by Innovate UK to research and develop new drugs directed against a unique SARS-CoV2 protein utilizing STORM’s proprietary RNA epigenetic platform.
STORM has established a novel drug discovery platform to enable the identification of first in class inhibitors targeting RNA-modifying enzymes for oncology, infection, and inflammatory diseases. The platform is…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF
AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING
- Demonstrates best-in-class potential for effective disease management in patients requiring high daily doses of insulin
- Delivers significantly accelerated absorption of insulin compared to gold standard, NovoRapid®(100U/mL), despite a 5-fold increase in concentration
- A critical enabler in the development of next generation miniaturised insulin-delivery systems
- Favourable safety profile…
Leading global drug development consultancy Boyds has appointed experienced clinical researcher Caroline Corbett as Director of Clinical Operations to support the team’s continued growth and the rising demand for its specialist clinical trial expertise.
As Director of Clinical Operations at Boyds, Caroline will support Dr Karen O’Hanlon, Vice President of Clinical Operations, with the ongoing growth and development of the clinical operations team and service offering.
Based at Boyds’ Cambridge office, Caroline will focus on the delivery of study start-up activities, including site selection…
Cambridge Innovation Capital (CIC), the venture capital investor focused on building world-leading deeptech and life sciences businesses connected with the Cambridge ecosystem, has raised £225 million ($300 million) for its oversubscribed second fund (Fund II).
CIC was founded to improve the success rate of businesses originating from the University of Cambridge and the broader Cambridge ecosystem, to encourage more academics and entrepreneurs from the area to build businesses. In addition to its portfolio companies, CIC has co-founded two Cambridge-based business accelerators, DeepTech Labs…